Clinical Trials

The purpose of this study is to see if varenicline will decrease alcohol consumption and increase alcohol abstinence rates when given to alcoholic patients for both alcohol and smoking cesation treatment.

This protocol will investigate the neurobiological underpinnings of alcohol craving in recently detoxified alcoholic drinkers utilizing novel functional brain imaging. This clinical magnetic resonance spectroscopy (MRS) study will investigate whether glutamate and other brain metabolites correlate to measures of alcohol craving severity.

Alcohol abuse and dependence remain highly prevalent and disabling. Persistent low treatment rates and high relapse rates indicate the need for more research in treatment of alcoholism. It is well known that craving is a core component of alcohol dependence associated with relapse. Unfortunately current methods of assessment of craving intensity are based on the subjective response to questionnaires. Identification of the physiological correlates of craving intensity holds promise for improving our understanding and prediction of which patients will be at higher risk of relapse. Number of studies showed that cue induced craving for alcohol was associated with changes in ...

The purpose of this study is to evaluate the safety, tolerability and effectiveness of V117957, compared to placebo, in subjects with alcohol use disorder (AUD) who experience insomnia associated with alcohol cessation.

The purpose of this project is to identify biomarkers by discovery of genomic and metabolomic markers associated with response to acamprosate treatment. To achieve this we will use “pharmacometabolomics-informed pharmacogenomics” such as generation a panel of iPSCs (stem cells) to discover biomarkers.  A new prospective randomized placebo-controlled trial of 3 month long treatment with acamprosate/placebo will provide new biospecimens, in addition to previously collected biospecimens, to enable the search for genetic and metabolomic biomarkers associated with sobriety or relapse in participants of this new study.

The purposes of this study are to demonstrate the feasibility of assessing delayed dim light melatonin onset (DLMO) in patients with comorbid AUD and DSWPD utilizing a combination of questionnaires and laboratory assay of salivary melatonin levels, and to examine the impact of low-dose melatonin on SOL and overall sleep quality in patients withcomorbid AUD and DSWPD with delayed DLMO compared to those without delayed DLMO.

The purpose of this study is to evaluate the safety of acamprosate in individuals with alcohol-use disorder (AUD) and alcohol-related liver disease.

The primary aim of this study is to define a comprehensive digital phenotype that predicts risk for near-future relapse or relapse in alcohol use in patients with alcohol-associated liver disease.

The secondary aim of this study is to assess the relationship between this digital phenotype and markers of disease severity outcome, including MELD score and readmission rates.